Key facts
- Qnomx’s last known valuation is $6.6M (Apr 2025).
- It has raised $1.8M; the latest was Early Stage VC ($1.8M) in Apr 2025.
- Notable investors include Superangels, JVH Ventures, Heal Capital, Becker Ventures, Goodface Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Qnomx
- ·The full record, as it builds
Funding rounds
No funding rounds for Qnomx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qnomx
Provider of cancer genomic analysis services designed to support informed treatment decisions. The company offers expert cancer genomics case review and consultation, leveraging curated data from peer-reviewed literature and a proprietary knowledge base with compliance and security measures such as GDPR compliance and data deletion after service delivery, enabling healthcare providers to access timely, expert analysis and consultation support for precision oncology.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2022
- Employees
- 6
- Website
- qnomx.ai/
- Ownership
- Privately Held (backing)
Qnomx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qnomx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qnomx in its N-PORT filings yet. We sweep new filings monthly.